GTE Bio

GTE Bio is a clinical-stage biotechnology company dedicated to developing next-generation immunotherapies for cancer, with a primary focus on solid tumors. The company utilizes its proprietary Gene-Targeted Engineering (GTE) platform to design and optimize CAR-T cell therapies and therapeutic antibodies that aim to overcome the immunosuppressive microenvironment of solid tumors. Its lead candidate, GTE-101, is a CAR-T therapy targeting Claudin 18.2 that has entered clinical trials for patients with advanced gastric and pancreatic cancers. Headquartered in Suzhou, China, with research operations in the United States, GTE Bio integrates advanced gene editing and cell engineering technologies to create high-potency precision medicines. The company is backed by prominent venture capital firms and continues to expand its pipeline into diverse oncological indications.